MK-0431/ONO-5435 [sitagliptin] phase III clinical study - glimepiride add-on study for patients with type 2 diabetes mellitus.
Phase of Trial: Phase III
Latest Information Update: 27 May 2016
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2009 Actual patient number changed from 138 to 195 as reported by ClinicalTrials.gov.
- 14 Jun 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History